Week 15
Cloning and embryonic stem cells
The last recorded lecture, by Professor Martin, asks whether development really runs only one way, from a totipotent zygote to stable differentiated cells. Lecture 35 follows early mammalian development through cleavage to the blastocyst, where the first fate decision separates the inner cell mass (the embryo proper, marked by the transcription factor Oct4 and the source of embryonic stem cells) from the trophoblast (the embryo's part of the placenta). It then presents the two experiments behind the 2012 Nobel Prize. Gurdon transplanted nuclei from albino Xenopus tadpoles into enucleated eggs and got albino frogs, and Dolly the sheep later showed the same in a mammal, though only after more than 400 nuclear transfers: differentiated cells keep the whole genome, and differentiation is a change in gene expression. Yamanaka showed that four transcription factors reprogram fibroblasts into induced pluripotent stem cells, which can be directed into cell types such as beating heart cells for regenerative medicine without MHC-based rejection. The class ended by debating human cloning and gene editing after the 2018 claim of gene-edited babies in China. Recitation 22 reviews HIV combination therapy alongside potency and cloning. Lecture 36 (In the news, December 12) was not recorded; lecture 34 announced it would include a student topoisomerase demonstration and a 7.016 Jeopardy review.
Objectives
- Define totipotent, pluripotent, multipotent, unipotent, and differentiated cells, place the zygote, inner cell mass, embryonic stem cells, hematopoietic stem cells, and neurons on that scale, and sketch how potency falls over developmental time
- Describe early mammalian development from zygote through cleavage divisions to the blastocyst, and the first fate decision between the inner cell mass (embryo proper, Oct4-positive) and the trophoblast (embryonic part of the placenta)
- Explain how somatic cell nuclear transfer into an enucleated oocyte (Gurdon's albino Xenopus nuclei, Dolly the sheep) shows that differentiated cells keep the full genome, distinguish reproductive cloning from deriving embryonic stem cells from the cloned embryo, and explain why efficiency falls as donor cells become more differentiated
- Explain how expressing Oct4, Sox2, Klf4, and c-Myc reprograms differentiated cells into induced pluripotent stem cells, and why patient-derived cells differentiated in vitro could replace lost cells without transplant rejection
- Predict the outcome of cloning from a nucleus whose DNA has been permanently rearranged, such as a mature B cell with V(D)J-joined antibody genes
- Weigh arguments for and against human reproductive cloning and germline gene editing, using the 2018 claim of gene-edited babies as a case
Reading
| Life 11.6 | Cell death and apoptosis, the counterpart to cell division that lecture 24 tied to stem cells and tissue homeostasis. MIT also assigned 11e 19.1 and 19.5 on development and stem cells, which have no counterpart in the 12th edition, so lecture 35 and Recitation 22 are the source for potency, nuclear transfer, and induced pluripotent stem cells. |
Lectures
| 35 | Reproductive cloning and embryonic stem cells | 34:28 |
| 34:28 |
Recitations
Recitation 22: HIV, potency, and cloning
Reviews lectures 34 and 35: how HIV enters helper T cells and why it mutates so fast, then fate and potency in development (totipotent to differentiated), embryonic and induced pluripotent stem cells, and somatic cell nuclear transfer for reproductive and therapeutic cloning, including its very low efficiency.
- (1a) Combination therapy is the current strategy for treating HIV patients. Why is it more successful than a single drug at preventing the emergence of drug-resistant clones?
- (1b) In a combination therapy, which protein does each drug target if it prevents: HIV binding to the target cell; integration of the HIV genome into the host genome; cleavage of the viral polyprotein into individual proteins?
- (2) Draw a graph of cell potency against time during the development of an organism, starting from the zygote (one-cell stage).
- (3) Any somatic cell can be used for somatic cell nuclear transfer (SCNT). What does this tell you about the genome of somatic cells?
- (4) You clone animals by SCNT using the nucleus of a mature B cell. Would this change the B cell receptor diversity and the functioning of the clone's immune system?